Ignite Creation Date:
2025-12-25 @ 2:11 AM
Ignite Modification Date:
2025-12-27 @ 11:01 PM
Study NCT ID:
NCT00292760
Status:
COMPLETED
Last Update Posted:
2009-12-16
First Post:
2006-02-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion
Sponsor:
Royal Marsden NHS Foundation Trust
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
None
Start Date Type:
None
Primary Completion Date:
None
Primary Completion Date Type:
None
Completion Date:
None
Completion Date Type:
None
First Submit Date:
2006-02-15
First Submit QC Date:
None
Study First Post Date:
2006-02-16
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2009-12-15
Last Update Post Date:
2009-12-16
Last Update Post Date Type:
ESTIMATED